Key points
- The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
- These recommendations become official ÐÇ¿ÕÓéÀÖ¹ÙÍø policy once adopted by ÐÇ¿ÕÓéÀÖ¹ÙÍø's Director.
- Learn about current and historical ACIP recommendations for hepatitis A vaccine.
Published in Morbidity and Mortality Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the ÐÇ¿ÕÓéÀÖ¹ÙÍø regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the ÐÇ¿ÕÓéÀÖ¹ÙÍø Director and, if adopted, are published as official ÐÇ¿ÕÓéÀÖ¹ÙÍø/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT Hepatitis A Vaccine Recommendations
MMWR, July 3, Vol 69(5);1–38
Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020
Print version
ARCHIVED Hepatitis A Immunization Publications
For your convenience, these archived publications can be used for historical and research purposes.
MMWR, February 15, Vol 68(6);153–156
Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness
Print version
MMWR, November 2, 2018, Vol 67(43);1216–1220
Updated Recommendations from the ACIP for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel
Print version
MMWR, September 18, 2009, Vol 58(36);1006-1007
Updated Recommendations from the ACIP for Use of Hepatitis A Vaccine in Close Contacts of Newly Arriving International Adoptees
Print version
MMWR, October 12, 2007, Vol 56(40);1057
Notice to Readers: FDA Approval of an Alternate Dosing Schedule for a Combined Hepatitis A and B Vaccine (Twinrix®)
Print version
MMWR, October 19, 2007, Vol 56(41);1080-1084
Update: Prevention of Hepatitis A After Exposure to Hepatitis A Virus and in International Travelers. Updated Recommendations of the ACIP
Print version
MMWR, May 19, 2006, Vol 55(RR-07);1-23
Prevention of Hepatitis A Through Active or Passive Immunization
Print version
MMWR, December 9, 2005, Vol 54(48);1235-1236
Notice to Readers: FDA Approval of Havrix® (Hepatitis A Vaccine, Inactivated) for Persons Aged 1-18 Years
Print version
MMWR, October 14, 2005, Vol 54(40);1026
Notice To Readers: FDA Approval of VAQTA® (Hepatitis A Vaccine, Inactivated) for Children Aged >1 Year
Print version
MMWR, September 21, 2001, Vol 50(37);806-7
Notice to Readers: FDA Approval for a Combined Hepatitis A and B Vaccine
Print version